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Abstract 11 
Carbopol® 971 and poly(2-ethyl-2-oxazoline) form hydrogen-bonded interpolymer complexes 12 
in aqueous solutions and their complexation is strongly dependent on solution pH. This work 13 
investigated the complexation between these polymers in aqueous solutions. The compositions 14 
of interpolymer complexes as well as the critical pH values of complexation were determined.  15 
The structure of these complexes was studied in solutions using transmission electron 16 
microscopy and in solid state using elemental analysis, FTIR spectroscopy and differential 17 
scanning calorimetry. Solid compacts were prepared based on interpolymer complexes and 18 
physical blends of these polymers and their swelling behaviour was studied in aqueous 19 
solutions mimicking the fluids present in the gastrointestinal tract. These materials were used 20 
to prepare oral formulations of mesalazine and its release from solid matrices was studied in 21 
vitro. It was demonstrated that the complexation between Carbopol® 971 and poly(2-ethyl-2-22 
oxazoline) has a profound effect on the drug release from matrix tablets. 23 
 24 
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1. Introduction 30 
Hydrophilic polymers and their combinations are often used to formulate dosage forms as they 31 
provide a number of unique features required for successful drug delivery. When polymer 32 
combinations are used for this purpose the performance of the resulting material is often 33 
affected by specific attractive interactions occurring between them. The most common types 34 
of specific interactions are electrostatic attraction and hydrogen bonding. Electrostatic 35 
attraction may occur in combinations of oppositely charged polyelectrolytes and typically 36 
results in formation of interpolyelectrolyte complexes (Mustafin, 2011).  Hydrogen-bonded 37 
interpolymer complexes (IPC) are commonly formed as a result of interactions between 38 
polycarboxylic acids, acting as proton donors, and non-ionic water-soluble polymers, 39 
exhibiting proton-accepting properties (Bekturov and Bimendina, 1981; Kemenova et al, 1991; 40 
Khutoryanskiy, 2007; Kharlampieva et al, 2009).   41 
Poly(2-oxazolines) is an interesting class of functional materials, which is represented by 42 
several polymers soluble in water (e.g. poly(2-methyl-2-oxazoline), poly(2-ethyl-2-oxazoline), 43 
poly(n-propyl-2-oxazoline, etc). The synthesis of these polymers was first described in the 44 
1960s; however, they received recognition as highly promising biomedical materials only in 45 
the last decade (Hoogenboom, 2009; Viegas et al, 2011; Luxenhofer et al, 2012; de la Rosa, 46 
2014; Hoogenboom and Schlaad, 2017; Lorson et al, 2018). Numerous recent studies reported 47 
the use of poly(2-oxazolines) in the design of micellar structures for drug delivery (Hruby et 48 
al, 2010), vectors for gene therapy (Lehner et al, 2017), hydrogels (Farrugia et al, 2013), 49 
polymer-drug/protein conjugates (Mero et al, 2008), and mucus-penetrating nanoparticles 50 
(Mansfield et al, 2015; Mansfield et al, 2016). Polyoxazolines are generally non-toxic, 51 
biocompatible, and bioinert, which makes them highly promising for various biomedical 52 
applications. These polymers are often viewed as an alternative to polyethylene glycols 53 
(Bludau et al 2017; Khutoryanskiy, 2018).   54 
Water-soluble poly(2-oxazolines) exhibit a number of interesting physicochemical properties 55 
such as temperature-responsive behaviour (Christova et al, 2003; Diehl and Schlaad, 2009; 56 
Ambreen and Siddiq, 2014) and proton-accepting ability that facilitates their interactions with 57 
proton-donating polymers (Kim et al, 2002). These properties have been successfully utilised 58 
in the development of self-assembled materials such as micelles (Filippov et al, 2017), 59 
interpolymer complexes and polymeric blends (Dai et al, 1994; Isasi et al, 1996; Kim et al, 60 
2002), and multi-layered constructs (Su et al, 2017; Su et al, 2018).  61 
The application of poly(2-oxazolines) in the design of solid dosage forms for drug delivery has 62 
also received recent interest, but it is still studied insufficiently (Claeys et al, 2012; Policianova 63 
et al, 2014; Fael et al, 2018). Recently, interpolymer complexes and physical blends of poly(2-64 
ethyl-2-oxazoline)s and two Carbopol® grades (Carbopol® 974 and Carbopol® 971) were 65 
reported for the development of mucoadhesive tablets for buccal delivery of hydrocortisone 66 
(Ruiz-Rubio et al, 2018). It was demonstrated that the interaction between these polymers is 67 
pH-dependent and the behaviour of tablets is strongly affected by the interactions between the 68 
polymers. Taking the pH-responsive nature of these complexes they could also be of interest 69 
as materials for oral drug delivery, where a dosage form will experience different pH 70 
environments during its transit through gastrointestinal tract.  71 
In the present study the complexation between Carbopol® 971 and poly(2-ethyl-2-oxazoline) 72 
of different molecular weights was explored both in solutions and in solid state. The effect of 73 
solution pH on the complexation between polymers was explored and the critical pHs of 74 
complexation were determined. The structure of interpolymer complexes in solid state was 75 
studied by elemental analysis, FTIR spectroscopy and differential scanning calorimetry. Solid 76 
compacts composed of either IPCs or physical mixtures (PMs) were studied in the media 77 
mimicking different parts of gastrointestinal tract. These solid materials were used to formulate 78 
a model drug mesalazine relevant for gastrointestinal drug delivery and its release from the 79 
dosage forms was studied in vitro.  80 
 81 
2. Materials and Methods  82 
2.1. Materials 83 
Poly(2-ethyl-oxazoline)s (5000, 50000, 500000 g mol-1; named as POZ 5 kDa, POZ 50 kDa 84 
and POZ 500 kDa in the text, respectively) were purchased from Sigma-Aldrich (Irvine, UK) 85 
and Carbopol® 971 (weakly cross-linked, 4000-11000 cP, 3000 kDa) (named as C971 in the 86 
text), was generously donated by Lubrizol Advanced Materials (Wickliffe, OH, U.S.A.). 87 
Potassium dihydrogen phosphate, hydrochloric acid and sodium hydroxide were provided by 88 
Sigma-Aldrich (Irvine, UK) and used for preparing the media mimicking conditions of gastro-89 
intestinal tract. Mesalazine (5-aminosalicylic acid, 5-ASA) was purchased from Sigma-Aldrich 90 
(Irvine, UK). A Milli-Q water purification system from Millipore (Bedford, MA, U.S.A.) was 91 
used for preparation of all solutions. 92 
 93 
2.2. Methods 94 
2.2.1 IPC formation 95 
Aqueous mixtures were prepared by mixing 0.002 unit-mol/L individual polymer solutions in 96 
deionized water. Solutions were mixed to give different unit molar ratios of the polymer 97 
components. The obtained interpolymer complexes (IPCs) were left for 1 hour in the media, 98 
and then turbidity of all solutions was measured spectrophotometrically (Lambda 25, Perkin 99 
Elmer, Norwalk, CT, U.S.A.) at 400 nm. The complexation between C971 and POZ was 100 
initially evaluated in water without adjusting the pH.  101 
 102 
For pHcrit determination, samples were typically analyzed in solutions, whose pH 103 
ranged from 3.0 to 8.0, which was adjusted by adding small portions of 0.1 M NaOH or 0.1 M 104 
HCl. The pH measurements were performed using a portable pH meter Orion Star A 325 105 
(Thermo Scientific, U.S.A.) with Orion™ ROSS Ultra™ low maintenance pH/ATC Triode™ 106 
(Thermo Scientific, U.S.A.). The turbidity of these solutions was measured at 400 nm using a 107 
UV/Vis-spectrophotometer (Lambda 25, Perkin Elmer, Norwalk, CT, U.S.A.). Turbidity 108 
readings were taken immediately after adjusting pH. All experiments were repeated in 109 
triplicate, and the turbidity values are reported as mean ± standard deviation. 110 
 111 
The composition with the maximal turbidity was selected for the tablet formulation. IPCs were 112 
prepared by mixing 0.1 M POZ and 0.125 M C971 solutions in acetate buffer (рН=3.5) and at 113 
constant temperature. After isolation of the precipitates from the solutions, they were washed 114 
twice with demineralized water and the IPCs were subsequently freeze-dried for 2 days at -27 115 
°C (Labconco® Freeze Dry System, FreeZone 1 L, MO, U.S.A.). The dried IPCs were ground 116 
with A 11 basic grinder (IKA® Werke GmbH, Staufen, Germany) and used for further study. 117 
The samples were stored in tightly sealed containers at room temperature. 118 
 119 
2.2.2. Transmission electron microscopy (TEM) 120 
TEM images of IPC were acquired using a JEM 2100 plus TEM (Jeol Ltd., Watchmead 121 
England) at 200 kV. For sample preparation, the copper grids were brought in contact with 122 
dispersions of IPC for 30 s and then dried off with a filter paper. The pH of polymer mixtures 123 
in aqueous solutions prior to TEM examination was adjusted by adding small amounts of 0.2 124 
mol/L HCl or NaOH and was measured using a digital pH-meter (Metrohm, Herisau, 125 
Switzerland). 126 
 127 
2.2.3. Elemental analysis  128 
The composition of freeze-dried IPC (C971/POZ 50 kDa and C971/POZ 500 kDa) samples 129 
and physical mixture (PM) samples before, during, and after swelling testing were investigated 130 
by elemental analysis using a Thermo Flash 2000 CHNS/O elemental analyzer (Thermo Fisher 131 
Scientific, Paisley, UK). PMs were prepared by mixing C971 and POZ powders at 1.25:1 molar 132 
ratio. 133 
 134 
2.2.4. Fourier transform infrared spectroscopy (ATR-FTIR)  135 
ATR-FTIR-spectra were recorded using a Nicolet iS5 FTIR spectrometer (Thermo Scientific, 136 
Waltham, MA, U.S.A.). The untreated freeze-dried samples of solid IPC (C971/POZ 50 kDa 137 
and C971/POZ 500 kDa) and PM samples before, during, and after swelling testing were 138 
directly mounted over the iD5 smart single bounce ZnSe ATR crystal. The spectra were 139 
analyzed using OMNIC spectra software. 140 
 141 
2.2.5. Thermal analysis  142 
Modulated DSC (mDSC) measurements were carried out using a Discovery DSC™ (TA 143 
Instruments, New Castle, DE, U.S.A.), equipped with a refrigerated cooling system (RCS90). 144 
TRIOSTM software (version 3.1.5.3696) was used to analyze the results (TA Instruments, New 145 
Castle, DE, U.S.A.). Tzero aluminum pans (TA Instruments, New Castle, DE, U.S.A.) were 146 
used in all calorimetric studies. The empty pan was used as a reference and the mass of the 147 
reference pan and of the sample pans were taken into account. Dry nitrogen at 50 mL/min was 148 
used as a purge gas through the DSC cell. Indium and n-octadecane standards were used to 149 
calibrate the DSC temperature scale; enthalpic response was calibrated with indium. The 150 
modulation parameters used were: 2 °C/min heating rate, 40 s period and 1 °C amplitude. 151 
Calibration of heat capacity was done using sapphire. Samples were analyzed from 0 to 200 152 
°C.  153 
 154 
2.2.6. Preparation of Tablets  155 
To determine the degree of swelling, flat-faced tablets of 100 mg polymer carrier were prepared 156 
by compressing the given amount of powders (C971, POZ 50 kDa, POZ 500 kDa, PMs, and 157 
IPCs) in a hydraulic press (Perkin Elmer, Waltham, MA, U.S.A.), equipped with flat-faced 158 
punches with 13 mm diameter (Pike Technologies, Madison, WI, U.S.A.) with a compression 159 
pressure of 6.24 MPa. For dissolution testing, 150 mg biconvex tablets (100 mg 5-ASA and 50 160 
mg polymer carrier) with 6 mm diameter were prepared by compressing the given amount of 161 
the polymer carriers at 6.24 MPa using a hydraulic press (Perkin Elmer, Waltham, MA, 162 
U.S.A.). 163 
 164 
2.2.7. Determination of the Degree of Swelling of Matrices 165 
Swelling was investigated under conditions, mimicking the gastro-intestinal tract (GIT): the 166 
first two hours in simulated gastric medium (0.1 M HCl; pH 1.2), then four hours in simulated 167 
intestinal medium (phosphate buffer; pH 6.8).  168 
 169 
2.2.7.1. Gravimetric measurements 170 
The polymer matrices (d=13 mm) were placed in a tarred basket (from USP I apparatus), which 171 
was immersed into a thermostatted bath at 37.0 ± 0.5 °C on IC control eco 18c (IKA® Werke 172 
GmbH, Staufen, Germany). The volume of the medium was 100 mL. The basket was removed 173 
from the medium every 15 min within the first hour and then every 30 min; the tablets were 174 
carefully dried using a filter paper and weighed. The degree of swelling (H, %) was calculated 175 
using the following equation:  176 
H% = (m2 - m1 /m1)×100, 177 
where m1 is the weight of the dry sample and m2 is the weight of the swollen sample. 178 
 179 
2.2.7.2. Image analysis 180 
The polymer matrices (d=13 mm) were placed into petri dishes with 40 mL of the medium 181 
preheated to 37.0 ± 0.5°C. The petri dishes with matrices were removed from thermostatted 182 
bath every 1 hour, placed on a graph paper and changes in the sizes of the matrices were 183 
measured. 184 
 185 
2.2.8. Release of mesalazine (5-ASA) from the polymer matrices in GIT mimicking conditions 186 
The release of 5-ASA from the matrix tablets was performed under sink conditions at 37.0 ± 187 
0.1 °C using the USP I Apparatus (the off-line dissolution tester DT 828 with an auto sampler 188 
ASS-8, a fraction collector FRL 824 and a peristaltic pump ICP-8 (Erweka, Heusenstamm, 189 
Germany)). The basket rotation speed was 100 rpm and the volume of the medium was 900 190 
mL. The release was investigated for 6 h under GIT mimicking conditions, where the pH of 191 
the release medium was gradually increased: 2 h in 0.1 M hydrochloric acid (pH = 1.2) and 192 
then in phosphate buffer solution (pH = 6.8) until the end of experiment. Aliquots (5 mL) of 193 
solution were automatically taken at specific time intervals, and the volume of medium was 194 
made up to the original value by adding fresh dissolution medium. The amounts of 5-ASA 195 
released in the dissolution medium were determined by UV/Vis-spectrophotometry at 302 nm 196 
(at pH=1.2) and 330 nm (at pH=6.8), respectively (Lambda 25; Perkin-Elmer, Waltham, MA, 197 
U.S.A.). Results are given as the mean values of three determinations ± standard deviations. 198 
Release rates (RR) were determined by calculating the slopes of the released 5-ASA (%) vs 199 
time profiles in the first 120 min of experiment.   200 
 201 
Results and Discussion 202 
3. Formation of interpolymer complexes in aqueous solutions 203 
Simple mixing of 0.002 unit-mol/L aqueous solutions of C971 and POZ (without adjustment 204 
of pH) at room temperature results in immediate appearance of turbidity, which was used to 205 
estimate the compositions of IPCs formed. Figure 1 presents the turbidity data for the polymers 206 
mixed at different molar ratios. It is widely recognised that the maximal values of turbidity 207 
generally correspond to the compositions of IPC (Satoh et al, 1989; Takayama et al, 1990; 208 
Moustafine et al, 2006). POZ 50 kDa exhibited greater ability to increase the turbidity of 209 
solution mixtures with the maximal values observed at [C971]:[POZ]=1.25:1 mol/mol. Similar 210 
trend is observed for POZ 500 kDa; however, its turbidity is significantly lower (p<0.005). 211 
POZ 5 kDa exhibited much lower ability to increase the solution turbidity in mixtures with 212 
C971.  213 
(Figure 1 is here).  214 
It could be anticipated that these polymers should form 1:1 complexes, i.e. one unionised 215 
carboxylic group of C971 forms hydrogen bond with one proton-accepting nitrogen according 216 
to the proposed scheme (Figure 2). A deviation from 1:1 ratio observed in our experiments 217 
could be related to two factors: (1) a weakly cross-linked nature of C971, which results in steric 218 
hindrances and not complete availability of carboxylic groups of polyacid to interact with POZ; 219 
(2) under the pH conditions of this experiment not all carboxylic groups of C971 are non-220 
ionised and capable of forming hydrogen bonds with POZ. This result agrees with the previous 221 
studies of C971 – POZ complexes using gravimetric analysis (Ruiz-Rubio et al, 2018).  222 
(Figure 2 is here) 223 
Previously, Khutoryanskiy and co-workers (Mun et al, 2000; Nurkeeva et al, 2003; 224 
Khutoryanskiy et al, 2004a; Khutoryanskiy et al, 2004b; Nurkeeva et al, 2005; Zhunuspayev 225 
et al, 2008) have demonstrated that the complexation between poly(carboxylic acids) and non-226 
ionic polymers is facilitated under acidic conditions and formation of colloidal IPCs is typically 227 
observed below a certain critical pH of complexation (pHcrit). pHcrit values were proposed as a 228 
criterion for the ability of a given pair of polymers to form hydrogen-bonded IPCs: greater 229 
pHcrit indicated a stronger ability of polymers to form complexes. To the best of our knowledge, 230 
the data on pHcrit of complexation involving poly(2-oxazolines) is still very limited in the 231 
literature. Su et al (2017) recently reported that the thickness of miltilayered films, formed 232 
using layer-by-layer deposition of poly(acrylic acid) (PAA) and POZ onto a solid substrate, 233 
showed a pH dependence, typical for hydrogen-bonded IPCs: a rapid increase in the film 234 
thickness is observed upon decrease in pH in the 3.5-4.0; above pH 4.0 the films did not form. 235 
The authors assigned the pH 3.5-4.0 to the critical pH of complexation between these polymers. 236 
In the present work the critical pHs were determined for Carbopol® 971 – POZ complexes 237 
using turbidimetric technique. Figure 3 shows the dependence of solution turbidity of 1:1 238 
polymer mixtures as a function of pH. It is clearly seen that a decrease in solution pH results 239 
in a rapid increase in turbidity at pH 4.8±0.2, when POZ 50 kDa was used to form IPC. This is 240 
slightly larger than the pHcrit reported by Su et al (2017) for complexes of POZ 50 kDa with 241 
PAA, but the discrepancy may be related to the difference in the methods used to determine 242 
pHcrit (film formation vs turbidimetric studies) and also the weakly cross-linked nature of 243 
Carbopol® 971 compared to PAA.  244 
 (Figure 3 is here) 245 
POZ with lower (5 kDa) and larger (500 kDa) molecular weights show their pHcrit around 4.2-246 
4.5 (no significant difference between pHcrit for 5 kDa and 500 kDa (p>0.05), but significantly 247 
lower than pHcrit for 50 kDa (p<0.05)). It is well known from the literature (Mun et al, 2000; 248 
Nurkeeva et al, 2003; Khutoryanskiy et al, 2004a; Khutoryanskiy et al, 2004b; Nurkeeva et al, 249 
2005) that increase in molecular weight of the polymers typically leads to increase in pHcrit. An 250 
anomalous lower complexation ability of POZ 500 kDa observed in experiments presented in 251 
Figure 1 (lower turbidity values) and also lower pHcrit values compared to POZ 50 kDa (Figure 252 
2) is possibly related to extremely large length of POZ 500 kDa macromolecules that approach 253 
so-called upper limit in molecular weights of polymers, previously reported by Bekturov and 254 
Bimendina (1981).  255 
A comparison of pHcrit values, previously reported for complexes of PAA and poly(N-vinyl 256 
pyrrolidone) pHcrit=4.85±0.05, poly(methyl vinyl ether) pHcrit=4.85±0.05, polyacrylamide 257 
pHcrit=3.00 ± 0.05, poly(ethylene oxide) pHcrit=2.88 ± 0.05, poly(vinyl alcohol) pHcrit=2.67 ± 258 
0.05 and some other polymers (Khutoryanskiy et al, 2004a), with the values determined for 259 
POZ in the present work allows to conclude that poly(2-ethyl-2-oxazoline) exhibits strong 260 
complexation ability. This ability to form IPCs is comparable with poly(N-vinyl pyrrolidone) 261 
and poly(methyl vinyl ether). It should be noted that in the current study we used polymer 262 
concentrations of 0.01 unit-mol/L similar to the measurements reported by Khutoryanskiy et 263 
al (2004a); however, the difference in the two studies is in the use of Carbopol® 971 (weakly 264 
cross-linked PAA, 3000 kDa) and linear PAA 450 kDa. 265 
In order to get an insight into the changes in the structure of IPCs at different pHs 266 
transmission electron microscopy (TEM) was used (Figure 4a). This experiment provides an 267 
excellent opportunity to see the evolution of IPC structure upon gradual decrease in solution 268 
pH. At pH 4.79, which is very close to pHcrit the structure of IPC looks like a network of fibrous 269 
material with the presence of some very small particles (18±6 nm). Upon decrease in pH to 270 
4.54 these particles become larger and denser (41±4 nm), but still are surrounded and connected 271 
to each other by fibrous material, which is possibly made of not fully complexed 272 
macromolecules. Under strongly acidic conditions the dense particles of IPC are fully formed; 273 
they are not stabilised by uncomplexed macromolecules and their size reaches 649±185 nm 274 
(pH 2.14) and 513±92 nm (pH 2.50). Very similar structural changes at different pHs were 275 
reported previously for the IPC formed by PAA and methylcellulose (Khutoryanskaya et al, 276 
2007). The proposed mechanism of IPC formation at different pHs is shown in Figure 4b.  277 
(Figure 4 is here) 278 
4. Physicochemical studies in solid state  279 
4.1.Fourier transform infrared spectroscopy (ATR-FTIR) 280 
ATR-FTIR spectrum of pure POZ independently from its molecular weight is characterized 281 
by the presence of a stretching band of amide I at 1635 cm-1. For C971, the band corresponding 282 
to the self-associated carboxylic group (COOH) is located at 1703 cm-1 (Nguyen et al., 2016; 283 
Ruiz-Rubio et al., 2018; Garipova et al, 2018). Clearly, the presence of POZ and C971 in the 284 
spectrum of the polymer mixture (PM) is indicated by their characteristic peaks with high 285 
intensities, such as the peak of the carboxyl stretching band of C971 (1705 cm-1) and a 286 
“shoulder” of amide I of POZ (1635 cm-1). In the IPC, a shift of the C=O bands could be 287 
observed to 1720 cm-1, while the amide I band shifts to 1600 cm-1. These bands are related to 288 
hydrogen bond formation between carboxyl groups of C971 and amide groups of POZ. 289 
(Figure 5 is here) 290 
4.2. Thermal analysis  291 
Figure 6(a, b) shows the DSC thermograms of C974, POZ 50 kDa (a), POZ 500 kDa (b), 292 
their PMs and IPCs. Carbopol 974 presents a Tg at 132.6 oC, whereas the Tg of POZ 50 and 293 
POZ 500 kDa are detected at 51.7 and 56.2oC, respectively. The presence of two unchanged 294 
Tg values in the PM prepared from C971 and both POZ samples (50 and 500 kDa) is indicating 295 
a phase separation of the polymers, i.e., confirmed that they were  not molecularly miscible 296 
(Moustafine et al., 2011, 2013). The IPCs of these polymers present an intermediate glass 297 
transition of 128.3-128.9 oC, similar to the changes observed in other IPCs and IPECs formed 298 
via hydrogen and ionic bonding, respectively (Khutoryanskiy et al, 2004b; Khutoryanskiy et 299 
al, 2004c; Ruiz-Rubio et al., 2018; Mustafin, 2011; Mustafin et al., 2011, 2015; Moustafine et 300 
al., 2011, 2013).  301 
 (Figure 6 is here).  302 
5. Swelling properties 303 
Swelling of the matrices in the media mimicking the gastrointestinal tract indicate that the 304 
compacts based on POZ 50 kDa and POZ 500 kDa completely dissolved at the end of the first 305 
hour (Figure 7). Matrices from C971 showed the highest values in swelling estimated by both 306 
methods (Figure 8a, b). During swelling, the matrices separated into two clearly visible layers, 307 
transparent external gel and non-hydrated white core. We believe that the external layer is 308 
formed due to the hydration of macromolecules with ionized carboxyl groups, while the core 309 
is still containing the chains with protonated COOH groups. Physical mixtures with POZ 50 310 
kDa (PM-1) and POZ 500 kDa (denoted as PM-2) show the values of matrix size similar to 311 
C971, but characterized by gradual release of POZ, localized in the external layer of the 312 
matrices in buffer medium. On the contrary, the swelling profiles of PM-1 and PM-2 are similar 313 
to each other only in acidic medium and have different character in the buffer at pH 6.8. The 314 
PM matrices based on POZ 50 kDa have two times lower swelling index in the buffer medium, 315 
compared to the swelling profile of PM with POZ 500 kDa. Moreover, in the case of two PM 316 
samples containing POZ with different molecular weight a stable swelling profile was observed 317 
only in the case of PM-1, relatively independent of the medium. PM-2 had a swelling profile 318 
similar to the matrices composed of pure C971, but with three times lower swelling degree as 319 
compared to the pure Carbopol®. These observations are believed to be resulting from 320 
hydrogen bonding effect between these polymers, which was probably happened within PM 321 
matrices under acidic conditions.  322 
(Figure 7 is here) 323 
Upon swelling, the polycomplex matrices showed the smaller dimensions, which means 324 
lower swelling ability. Additionally, the swelling profiles of IPC matrices showed similar 325 
character, but different swelling ability: in case of IPC formed with POZ 500 kDa the maximal 326 
swelling was approximately two times greater compared to the IPC with POZ 50 kDa. So, only 327 
PMs and IPCs with POZ 50 kDa show the most stable profiles with the lowest swelling degree, 328 
but in case of PM it has three times lower degree of swelling. The formulations consisting of 329 
proton-accepting non-ionic polymers (PVP, PEO, HPMC, HPC, MC, etc.) and proton-donating  330 
polycarboxylic acids – (polyacrylic / polymethacrylic acids, Carbopol® grades) could form 331 
IPCs under acidic pH and their swelling and drug release properties are controlled by three-332 
dimensional network structure, which was formed as a result of complex formation between 333 
the polymers following water penetration into the matrix (Takayama and Nagai, 1987; Satoh 334 
et al., 1989; Ozeki et al., 1998a, 1998b, 1999, 2000, 2005; Tan et all., 2001). 335 
(Figure 8 is here) 336 
For further analysis the matrices with gel layers and non-hydrated cores were taken out from 337 
the dissolution baskets in GIT- mimicking media at different time intervals (0, 2 and 6 h); their 338 
gel layers and non-hydrated cores were physically separated and freeze-dried. The algorithm 339 
of their physicochemical analysis is schematically illustrated in Figure 9.  340 
(Figure 9 is here)  341 
ATR-FTIR spectra (Figure 10) were recorded to gain a deeper insight into the spatial 342 
distribution of the macromolecules and their interactions in the matrix tablets containing PM 343 
based on POZ and C971 following their hydration. In the intact interpolymer complex, a shift 344 
of the C=O bands is observed to 1720 cm-1, while the amide I band shifts to 1600 cm-1. These 345 
bands are related to hydrogen bonding between carboxyl groups of C971 and amide groups of 346 
POZ. 347 
(Figure 10 is here) 348 
During the first 2 h in pH 1.2, the monolith polycomplex matrix has the composition 349 
similar to IPC without any differences in FTIR spectra and Tg values; however, there is a slight 350 
change in the composition of IPC from C971/POZ 1.4:1 into 1.5:1. During the swelling for 4 351 
h in the buffer solution (pH 6.8), the gel layer is formed that is composed of mainly C971 in its 352 
ionized hydrated form (appearance of a new band at 1557 cm-1). In contrast, the amount of 353 
POZ (according to the elemental analysis results, presented in Table 1) in the gel layer within 354 
4 h (pH 6.8) is decreased and reached 2.7:1 C971/POZ molar ratio. This is also evidenced by 355 
the presence of amide I stretching at 1633 cm-1 and the individual Tg value assigned to the pure 356 
POZ at 45.1±0.8 oC. Moreover, an increase in the Tg values from 125.2±0.3 to 127.9±0.7 oC 357 
and observed shifts of the characteristic bands at 1600 to 1606 cm-1 are related to the presence 358 
of hydrogen bonds between amide groups of POZ and carboxyl groups of C971; however, some 359 
segments of the IPC contain partly ionized COO- groups leading to dissociation of some 360 
interpolymer bonds. On the contrary, the non-hydrated core of IPC matrices still consists of the 361 
polycomplex structure, whose composition is close to the original IPC and IPC monolith matrix 362 
taken after its exposure to the acidic medium (pH 1.2). This result agrees with our studies using 363 
TEM technique.   364 
(Table 1 is here).  365 
The swelling behavior of PMs was found to be completely different from the tablets 366 
based on IPCs. Clearly, POZ and C971 dispersed uniformly in the intact tablet prior to 367 
hydration, as reflected by the presence of their characteristic peaks with high intensities in the 368 
spectrum of PM, such as the peak of the carboxyl stretching band of C971 (1704 cm-1) and a 369 
“shoulder” of amide I of POZ (1633 cm-1). According to above discussed mechanism of IPCs 370 
formation and also the literature data (Takayama and Nagai, 1987; Satoh et al., 1989; Ozeki et 371 
al., 1998a, 1998b; Tan et al., 2001; Zhang et al., 2016a, 2016b; Yusif et al., 2016; Szakonyi 372 
and Zelko, 2016, Nguyen et al., 2016), the passage of the tablets through pH 1.2 media 373 
facilitates strong interaction between the polymers. However, the spectral and thermal analysis 374 
results did not provide any evidence for the complexation under these conditions: the band 375 
corresponding to the self-associated carboxylic groups (COOH) located at 1704 cm-1 showed a 376 
very minor shift to 1707 cm-1 and the presence of amide I stretching was observed at 1622 cm-377 
1; Tg values at 51.7±0.9 oC and 131.9±0.8 oC observed are assigned to the pure POZ 50 kDa 378 
and C971, respectively. Moreover, some amount of pure POZ 50 kDa is leaching from the 379 
matrices, so the composition of mixture is changed from C971/POZ 1.4:1 to 2.2:1.  380 
During 4 h swelling of PM-1 in pH 6.8, the matrix composition becomes different to 381 
the composition of IPC. As it is seen from the data presented in Fig. 10 and Table 1, PM-1 382 
with POZ 50 kDa tablets completely transformed to the transparent gel with maximal gel-383 
forming capacity, which is clearly visible compared to pure C971 matrix. Additionally, in the 384 
ATR-FTIR spectrum of the freeze-dried gel layer (formed during 4 h swelling) the peak at 385 
1704 cm-1, corresponding to the carboxylic groups of C971, disappeared and was replaced by 386 
a new band at 1556 cm-1 assigned to the carboxylate ion (COO-). These findings indicated that 387 
the carboxylic groups in C971 were ionized when it came to contact with pH 6.8 buffer. This 388 
is also confirmed by higher Tg value (145.7±0.7 oC) assigned to the ionized C971 that is in 389 
good agreement with literature (Gomez-Carracedo et al., 2004). POZ was also present in the 390 
gel layer: the peak at 1630 cm-1 corresponding to the amide I stretching and somehow higher 391 
Tg value (59.4±0.9 oC) were assigned to POZ.  At 4 h in pH 6.8 (with a total swelling time of 392 
6 h), the gel layer lost substantial amount of POZ, as confirmed by remarkable change in 393 
C971/POZ composition from 1.4:1 to 5.8:1. So, the leaching of pure POZ from the gel layer is 394 
evident. The diffusion of POZ from the gel layer led to increase in the diffusional path length 395 
of the matrix, by which the drug release rate could be sustained (Ruiz-Rubio et al., 2018). 396 
POZ was predominantly present in the non-hydrated core at 4 h of swelling, evidenced 397 
by a strong band at 1627 cm-1. In particular, the peak at 1704 cm-1 assigned to the self-398 
associated carboxylic groups of C971 exhibited a gradual increase in the intensity with time 399 
and shifted to 1715 cm-1 corresponding to the carbonyl C=O stretching vibrations bands 400 
(Takayama and Nagai, 1987; Satoh et al., 1989; Ozeki et al., 1998a, 1998b, 1999, 2000, 2005). 401 
At 6 h of swelling, the non-hydrated core was completely transformed into hydrated form: Tg 402 
value assigned to POZ at 45.2±0.7 oC and slightly ionized C971 at 140.4±0.9 oC. Composition 403 
of the material after complete hydration also changed from C971/POZ 1.4:1 to 2.4:1. 404 
In addition, a frequency shift in the peak assigned to the amide I stretching group of 405 
POZ in the gel layer and non-hydrated core at 6 h of swelling changed from 1633 cm-1 to 1600 406 
cm-1 and appearance of characteristic Tg value at 125.2±0.3 oC, typical for strong hydrogen 407 
bonding between POZ and C971 were not observed.  408 
6. Drug release studies 409 
Mesalazine (5-ASA) is an anti-inflammatory drug that is used to treat some conditions of 410 
gastrointestinal tract, for example, inflammatory bowel disease (Quinteros et al, 2010). 5-ASA 411 
was used in this work as a model drug. The release of 5-ASA from the matrices was evaluated 412 
under GIT mimicking conditions. Figure 11 shows the dissolution profiles from the matrices 413 
based on C971 as well as their IPCs and PMs with POZ. Drug released faster from the matrices 414 
composed of pure POZ (RR=0.8513 %/min and 0.6665 %/min for 50 and 500 kDa POZ, 415 
respectively) and IPCs (RR=0.3676 %/min and 0.9016 %/min for 50 and 500 kDa POZ, 416 
respectively) compared to pure C971 (RR=0.1644 %/min) and PMs (0.1017 %/min and 0.1610 417 
%/min for 50 and 500 kDa POZ, respectively). Moreover, IPCs with POZ 500 kDa show faster 418 
release in acidic medium compared to all other samples. Additionally, the whole release 419 
process for this IPC is finished during the first 2 h in acidic medium. Understanding of this 420 
observation could come from our TEM results and evaluation of the swelling data. According 421 
to TEM data, under strongly acidic conditions the dense IPC particles with POZ 500 kDa are 422 
formed and their size reaches 649±185 nm (pH 2.14). Thus, in our release media (pH 1.2) the 423 
IPC particles became bigger that leads to formation of greater pores in the system compared to 424 
the IPC formed with POZ 50 kDa. Further evidence comes from the swelling properties of 425 
polycomplex matrices. The swelling index, estimated by two methods shows that IPC with 426 
POZ 500 kDa matrices exhibits greater swelling at pH 1.2 compared to IPC with POZ 50 kDa 427 
due to the formation of compact monolith structure with much lower porosity. Moreover, the 428 
observed phenomena also indicate that POZ is predominantly present on the surface of 429 
microgels formed from weakly cross-linked C971.  430 
Despite that diffusion of POZ 500 kDa from non-hydrated core to the gel layer may be slower 431 
due to its high molecular weight, compared to PM made from POZ 50 kDa, drug release process 432 
may proceed differently. It is known that hydrogen bonds in IPC matrices help increasing the 433 
gel strength to improve the release-retarding capacity of polymer matrix (Tan et al., 2001; 434 
Zhang et al., 2015, 2016; Yusif et al., 2016; Szakonyi and Zelko, 2016, Nguyen et al., 2016). 435 
Thus, in case of some proton-accepting non-ionic polymers (e.g. hydroxypropyl cellulose, 436 
HPC) and polycarboxylic acids (PAA or Carbopols), which could form IPC in acidic pH region 437 
and of course, in typical dissolution media, the release of drugs is controlled by the three-438 
dimensional network structure, which is affected by complex formation between these 439 
polymers following water penetration into the matrix (Satoh et al, 1989). If it can happen we 440 
will see a significant retardation of drug release, but mostly in the case of PM matrices and not 441 
for IPCs.  442 
The release rate of 5-ASA greatly decreases when the matrix was composed of PM. According 443 
to the abovementioned explanation of the swelling results, the decrease in the release rate in 444 
this case could be due to the complexation between the polymers, which has happened inside 445 
the matrix during penetration of dissolution media, resulting in the formation of three-446 
dimensional network. This leads to the formation of insoluble fibers in the matrix structure, 447 
which significantly retard the drug release process. 448 
(Figure 11 is here) 449 
Based on these results, the following explanation of drug release from IPC system could be 450 
proposed: in acidic medium, macromolecules of IPC swell significantly and 5-ASA partially 451 
dissolves from the surface of the matrix. The remaining amount of the undissolved drug after 452 
its transfer to another medium could continuously dissolve and diffuse from the swollen gel 453 
layer, that aсts as a driving force for 5-ASA molecules. On the contrary, at pH 6.8, hydrogen 454 
bonds between POZ and C917 are dissociated due to gradual ionization of COOH groups of 455 
C971 and 5-ASA, leading to destruction of interpolymer contacts (according to FTIR and 456 
mDSC data). Together with release of free POZ macromolecules (according to elemental 457 
analysis data) this facilitates dissolution of 5-ASA. Hence, C971 was responsible for sustaining 458 
drug release during the first 2 h to prevent the initial burst release. POZ then diffused gradually 459 
from the non-hydrated core to the gel layer, decreasing the gel strength and resulting in the 460 
gradual destruction of hydrogen bonding interaction between POZ and C971. For this reason, 461 
the rate of 5-ASA release in this polymer system (mixture-loaded matrix) progressively 462 
increased at latter stages.   463 
Additionally, drug release from different matrices could also be affected by specific 464 
interactions of mesalazine with C971 and POZ. As 5-ASA contains both proton-donating and 465 
proton-accepting groups in its structure, its interaction with Carbopols via ionic contacts 466 
(Quinteros et al, 2011) and with POZ via hydrogen bonding could not be ruled out completely.  467 
pH of dissolution medium is also expected to have effect on these interactions.  468 
  469 
Conclusions 470 
Formation of interpolymer complexes between Carbopol® 971 and poly(2-ethyl-2-oxazoline) 471 
of different molecular weights has been studied in aqueous solutions at different pHs. It was 472 
established that interpolymer hydrogen bonding is responsible for this complex formation; 473 
these interactions are possible only under acidic conditions. The evolution in the structure of 474 
the products of interpolymer interaction was studied in solutions with different pH. Upon a 475 
gradual decrease in solution pH the polymer mixtures evolved from completely non-interacting 476 
macromolecules to initial interpolymer associates, which then converted into primary compact 477 
IPC particles that were eventually transformed into spherical aggregates. Tablets were then 478 
prepared from interpolymer complexes and physical mixtures of Carbopol® 971 and poly(2-479 
ethyl-2-oxazoline) with and without a model drug (mesalazine). The structure of these 480 
materials was evaluated using FTIR and differential scanning calorimetry methods as well as 481 
swelling studies in the media mimicking conditions of gastrointestinal tract. It was established 482 
that the state of the polymers in the mixture and their swelling behavior is affected by the 483 
possibility of the complexation between them. The release of mesalazine from these tablets is 484 
also strongly influenced by the presence of interpolymer complexation. To the best of our 485 
knowledge, this is the first time when interpolymer complexes between Carbopol® 971 and 486 
poly(2-ethyl-2-oxazoline) were used to prepare solid dosage forms for gastrointestinal drug 487 
delivery. Potentially future research could compare poly(2-ethyl-2-oxazoline) with other non-488 
ionic polymers capable of forming interpolymer complexes with Carbopol® 971 (e.g. 489 
polyvinylpyrrolidone and polyethylene oxide) to establish if it could offer any advantages as a 490 
novel pharmaceutical excipient.  491 
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